• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Evolus Inc (NQ: EOLS )

    11.08 +0.23 (+2.12%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 498,227
    Open 10.83
    Bid (Size) 10.76 (1)
    Ask (Size) 11.48 (1)
    Prev. Close 10.85
    Today's Range 10.70 - 11.11
    52wk Range 7.070 - 15.43
    Shares Outstanding 54,576,156
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Evolus Announces Appointment of Albert G. White III to Board of Directors
    From Evolus
    Via Business Wire
    Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
    From Evolus
    Via Business Wire

    Performance

    YTD
    +10.91%
    +10.91%
    1 Month
    -14.83%
    -14.83%
    3 Month
    -19.45%
    -19.45%
    6 Month
    +10.91%
    +10.91%
    1 Year
    +53.04%
    +53.04%

    More News

    Read More
    Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
    From Evolus
    Via Business Wire
    Evolus: Chiseling Away At The Aesthetic Market
    Via Talk Markets
    Recap: Evolus Q4 Earnings
    Via Benzinga
    Earnings Outlook For Evolus
    Via Benzinga
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
    From Evolus
    Via Business Wire
    Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
    From Evolus
    Via Business Wire
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
    From Evolus, Inc.
    Via Business Wire
    EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Evolus Reports First Quarter 2024 Results and Provides Business Update
    From Evolus
    Via Business Wire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Evolus to Report First Quarter Financial Results on May 7, 2024
    From Evolus
    Via Business Wire
    Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
    From Evolus
    Via Business Wire
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Evolus
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
    From Evolus
    Via Business Wire
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
    From Evolus
    Via Business Wire
    Earnings Scheduled For March 7, 2024
    Via Benzinga
    Evolus Announces Results from European Head-to-Head Filler Trial
    From Evolus
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.